Grundlæggende statistik
| LEI | 391200MBZQNPFHIVKO34 |
| CIK | 924223 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BB Biotech AG
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| December 9, 2024 |
GBIO / Generation Bio Co. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d891686dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Generation Bio Co. (Name of Issuer) Common Stock (Title of Class of Securities) 37148K100 (CUSIP Number) December 5, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate t |
|
| November 18, 2024 |
MTEM / Molecular Templates, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d882996dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 608550208 (CUSIP Number) November 14, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to des |
|
| November 14, 2024 |
IONS / Ionis Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d877529dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 14)* Ionis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 462222100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to |
|
| November 14, 2024 |
ANNX / Annexon, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Annexon, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03589W102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| November 14, 2024 |
SAGE / Sage Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d826473dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sage Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 78667J108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to desi |
|
| November 14, 2024 |
EPIX / ESSA Pharma Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) November 1, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| April 22, 2024 |
EX-99.A 2 d807203dex99a.htm EX-99.A Exhibit A Exhibit A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned. BB Biotech AG Date: April 22, 2024 By: /s/ Martin Gubler Signatory Authority Name: Martin Gubler Title: Signatory Authority Date: April 22, 2024 By: /s/ Ivo B |
|
| April 22, 2024 |
ANNX / Annexon, Inc. / BB BIOTECH AG - SC 13G Passive Investment SC 13G 1 d807203dsc13g.htm SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Annexon, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03589W102 (CUSIP Number) April 17, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 13, 2024 |
US6085502085 / Molecular Templates, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d40123dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 608550208 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to desi |
|
| February 13, 2024 |
GBIO / Generation Bio Co. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Generation Bio Co. (Name of Issuer) Common Stock (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 13, 2024 |
AGIO / Agios Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d687782dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to |
|
| February 13, 2024 |
WVE / Wave Life Sciences Ltd. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d740975dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* WAVE LIFE SCIENCES LTD. (Name of Issuer) Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to de |
|
| February 13, 2024 |
BDTX / Black Diamond Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d771535dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09203E105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box |
|
| February 13, 2024 |
RVMD / Revolution Medicines, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Revolution Medicines, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76155X100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to des |
|
| February 13, 2024 |
SAGE / Sage Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d728625dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Amendment No. 1)* SCHEDULE 13G Under the Securities Exchange Act of 1934 Sage Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 78667J108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to desig |
|
| February 13, 2024 |
EPIX / ESSA Pharma Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 13, 2024 |
IONS / Ionis Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d749650dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 13)* IONIS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 462222100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to |
|
| February 13, 2024 |
EX-99.A Exhibit A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned. BB Biotech AG Date: February 6, 2024 By: /s/ Martin Gubler Signatory Authority Name: Martin Gubler Title: Signatory Authority Date: February 6, 2024 By: /s/ Ivo Betschart Signatory Authority Name: |
|
| February 13, 2024 |
MGNX / MacroGenics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d771056dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* MACROGENICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate t |
|
| January 24, 2024 |
ESPR / Esperion Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) January 19, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 24, 2024 |
ESPR / Esperion Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 17, 2023 |
EX-99.B 3 d459172dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 17, 2023 |
EX-99.A 2 d459172dex99a.htm EX-99.A Exhibit A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned. BB Biotech AG Date: February 17, 2023 By: /s/ Martin Gubler Signatory Authority Name: Martin Gubler Title: Signatory Authority Date: February 17, 2023 By: /s/ Ivo Betsc |
|
| February 17, 2023 |
SAGE / SAGE Therapeutics Inc / BB BIOTECH AG - SC 13G Passive Investment SC 13G 1 d459172dsc13g.htm SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Sage Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 78667J108 (CUSIP Number) February 9, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2023 |
EX-99.B 2 d398847dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
EX-99.B 2 d405438dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
EX-99.B 2 d400612dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
EX-99.B 2 d405844dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
MGNX / MacroGenics Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d401652dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* MACROGENICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate t |
|
| February 14, 2023 |
EX-99.B 2 d406969dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
EX-99.B 2 d443320dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
RVMD / Revolution Medicines Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d443320dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* REVOLUTION MEDICINES, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76155X100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Ch |
|
| February 14, 2023 |
MYOV / Myovant Sciences Ltd. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d398847dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* MYOVANT SCIENCES LTD. (Name of Issuer) Common Shares (Title of Class of Securities) G637AM102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to design |
|
| February 14, 2023 |
EX-99.B 2 d407274dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
KZR / Kezar Life Sciences Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d408330dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* KEZAR LIFE SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 49372L100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to des |
|
| February 14, 2023 |
SRRK / Scholar Rock Holding Corp / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d405844dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* SCHOLAR ROCK HOLDING CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 80706P103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box |
|
| February 14, 2023 |
IONS / Ionis Pharmaceuticals Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d394406dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12)* IONIS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 462222100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to |
|
| February 14, 2023 |
EX-99.B 2 d401652dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
EX-99.B 2 d394406dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
EX-99.B 2 d401650dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
ESPR / Esperion Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2023 |
SAGE / SAGE Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d401650dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sage Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 78667J108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to desig |
|
| February 14, 2023 |
EX-99.B 2 d408330dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
WVE / Wave Life Sciences Ltd / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d400612dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* WAVE LIFE SCIENCES LTD. (Name of Issuer) Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to de |
|
| February 14, 2023 |
MTEM / Molecular Templates Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d407274dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 608550109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to des |
|
| February 14, 2023 |
MRSN / Mersana Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d466514dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mersana Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 59045L106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the ap |
|
| February 14, 2023 |
BDTX / Black Diamond Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d417171dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09203E105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box |
|
| February 14, 2023 |
EPIX / ESSA Pharma Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d406969dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate t |
|
| February 14, 2023 |
EX-99.B 2 d398220dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
EX-99.B 2 d398218dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
GBIO / Generation Bio Co / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Generation Bio Co. (Name of Issuer) Common Stock (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 14, 2023 |
AGIO / Agios Pharmaceuticals Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d398218dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to d |
|
| February 14, 2023 |
EX-99.B 2 d466514dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
EX-99.B 2 d417171dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| September 30, 2022 |
RVMD / Revolution Medicines Inc / BB BIOTECH AG - SC 13G Passive Investment SC 13G 1 d290834dsc13g.htm SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 REVOLUTION MEDICINES, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76155X100 (CUSIP Number) September 22, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box |
|
| September 30, 2022 |
Exhibit A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned. |
|
| August 30, 2022 |
RDUS / Radius Health Inc / BB BIOTECH AG - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 14)* Radius Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 750469207 (CUSIP Number) BB Biotech AG Ivo Betschart Schwertstrasse 6 CH-8200 Schaffhausen, Switzerland +41 44 267 67 00 (Name, Address and Telephone Num |
|
| April 14, 2022 |
BDTX / Black Diamond Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09203E105 (CUSIP Number) April 11, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 11, 2022 |
ESPR / Esperion Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 11, 2022 |
AGIO / Agios Pharmaceuticals Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 11, 2022 |
CDTX / Cidara Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* CIDARA THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 171757107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 11, 2022 |
VYGR / Voyager Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* VOYAGER THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 11, 2022 |
MYOV / Myovant Sciences Ltd. / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* MYOVANT SCIENCES LTD. (Name of Issuer) Common Shares (Title of Class of Securities) G637AM102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 11, 2022 |
WVE / Wave Life Sciences Ltd / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* WAVE LIFE SCIENCES LTD. (Name of Issuer) Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 11, 2022 |
MTEM / Molecular Templates Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 608550109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 11, 2022 |
IONS / Ionis Pharmaceuticals Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* IONIS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 462222100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 11, 2022 |
KZR / Kezar Life Sciences Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* KEZAR LIFE SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 49372L100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 11, 2022 |
MGNX / MacroGenics Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* MACROGENICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 11, 2022 |
BDTX / Black Diamond Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09203E105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 11, 2022 |
GBIO / Generation Bio Co / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Generation Bio Co. (Name of Issuer) Common Stock (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 11, 2022 |
SAGE / SAGE Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d283396dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sage Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 78667J108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to desig |
|
| February 11, 2022 |
SRRK / Scholar Rock Holding Corp / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d283398dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* SCHOLAR ROCK HOLDING CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 80706P103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box |
|
| February 11, 2022 |
EPIX / ESSA Pharma Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 18, 2022 |
RDUS / Radius Health Inc / BB BIOTECH AG - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 13)* Radius Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 750469207 (CUSIP Number) BB Biotech AG Ivo Betschart Schwertstrasse 6 CH-8200 Schaffhausen, Switzerland +41 44 267 67 00 (Name, Address and Telephone Num |
|
| September 16, 2021 |
MRSN / Mersana Therapeutics Inc / BB BIOTECH AG - SC 13G Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MERSANA THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 59045L106 (CUSIP Number) September 10, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| August 17, 2021 |
EPIX / ESSA Pharma Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d220304dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) August 16, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the |
|
| August 11, 2021 |
SAGE / SAGE Therapeutics Inc / BB BIOTECH AG - SC 13G Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Sage Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 78667J108 (CUSIP Number) August 4, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which |
|
| June 11, 2021 |
MGNX / MacroGenics Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* MACROGENICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) June 9, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| May 28, 2021 |
ESPR / Esperion Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d174120dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) May 19, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to design |
|
| May 27, 2021 |
ESPR / Esperion Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) May 19, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| May 5, 2021 |
SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) April 29, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Ru |
|
| April 26, 2021 |
SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 608550109 (CUSIP Number) April 7, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 12, 2021 |
United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* KEZAR LIFE SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 49372L100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 12, 2021 |
SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* INTRA-CELLULAR THERAPIES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 46116X101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant |
|
| February 12, 2021 |
SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* MACROGENICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 12, 2021 |
United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* VOYAGER THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 12, 2021 |
SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* WAVE LIFE SCIENCES LTD. (Name of Issuer) Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 12, 2021 |
SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 608550109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 12, 2021 |
United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* IONIS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 462222100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 12, 2021 |
SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* HALOZYME THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 40637H109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 12, 2021 |
United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 12, 2021 |
SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* MYOVANT SCIENCES LTD. (Name of Issuer) Common Shares (Title of Class of Securities) G637AM102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 12, 2021 |
SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SCHOLAR ROCK HOLDING CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 80706P103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuan |
|
| February 12, 2021 |
United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* CIDARA THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 171757107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 12, 2021 |
SC 13G/A 1 d124139dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to d |
|
| February 11, 2021 |
SC 13G 1 d103037dsc13g.htm SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09203E105 (CUSIP Number) February 3, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pu |
|
| January 8, 2021 |
SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Generation Bio Co. (Name of Issuer) Common Stock (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| November 17, 2020 |
RDUS / Radius Health, Inc. / BB BIOTECH AG - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 12)* Radius Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 750469207 (CUSIP Number) BB Biotech AG Ivo Betschart Schwertstrasse 6 CH-8200 Schaffhausen, Switzerland +41 44 267 67 00 (Name, Address and Tele |
|
| November 4, 2020 |
MTEM / Molecular Templates, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 608550109 (CUSIP Number) October 26, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| May 19, 2020 |
RDUS / Radius Health, Inc. / BB BIOTECH AG - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* Radius Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 750469207 (CUSIP Number) BB Biotech AG Ivo Betschart Schwertstrasse 6 CH-8200 Schaffhausen, Switzerland +41 44 267 67 00 (Name, Address and Tele |
|
| February 14, 2020 |
KZR / Kezar Life Sciences, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* KEZAR LIFE SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 49372L100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 14, 2020 |
ESPR / Esperion Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2020 |
MYOV / Myovant Sciences Ltd. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* MYOVANT SCIENCES LTD. (Name of Issuer) Common Shares (Title of Class of Securities) G637AM102 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2020 |
WVE / WAVE Life Sciences Ltd. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* WAVE LIFE SCIENCES LTD. (Name of Issuer) Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 14, 2020 |
VYGR / Voyager Therapeutics, Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* VOYAGER THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 14, 2020 |
AGIO / Agios Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2020 |
IONS / Ionis Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* IONIS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 462222100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2020 |
SRRK / Scholar Rock Holding Corporation / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SCHOLAR ROCK HOLDING CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 80706P103 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuan |
|
| February 14, 2020 |
HALO / Halozyme Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* HALOZYME THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 40637H109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2020 |
CDTX / Cidara Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d835875dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* CIDARA THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 171757107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing This Statement) Check the appropriate box to des |
|
| February 14, 2020 |
MGNX / MacroGenics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* MACROGENICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 6, 2020 |
ITCI / Intra-Cellular Therapies Inc. / BB BIOTECH AG - SC 13G Passive Investment SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INTRA-CELLULAR THERAPIES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 46116X101 (CUSIP Number) January 30, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 29, 2020 |
THLD / Threshold Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G Passive Investment SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 608550109 (CUSIP Number) January 24, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| December 23, 2019 |
WVE / WAVE Life Sciences Ltd. / BB BIOTECH AG - SC 13G Passive Investment SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 WAVE LIFE SCIENCES LTD. (Name of Issuer) Common Stock (Title of Class of Securities) Y95308105 (CUSIP Number) December 17, 2019 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 13, 2019 |
TSRO / TESARO, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TESARO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 881569107 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| February 13, 2019 |
ESPR / Esperion Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d704774dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing This Statement) Check the appropriate box to d |
|
| February 13, 2019 |
MYOV / Myovant Sciences Ltd. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d693268dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* MYOVANT SCIENCES LTD. (Name of Issuer) Common Stock (Title of Class of Securities) G637AM102 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designa |
|
| February 13, 2019 |
HALO / Halozyme Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* HALOZYME THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 40637H109 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 13, 2019 |
MGNX / MacroGenics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d695656dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* MACROGENICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate t |
|
| February 13, 2019 |
VYGR / Voyager Therapeutics, Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* VOYAGER THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 13, 2019 |
CDTX / Cidara Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* CIDARA THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 171757107 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 13, 2019 |
IONS / Ionis Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* IONIS PHARMACEUTICALS, INC. (formerly Isis Pharmaceuticals, Inc.) (Name of Issuer) Common Stock (Title of Class of Securities) 462222100 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing This Statement) Check the appropriate |
|
| January 31, 2019 |
KZR / Kezar Life Sciences, Inc. / BB BIOTECH AG - SC 13G Passive Investment SC 13G 1 d663526dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 KEZAR LIFE SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 49372L100 (CUSIP Number) January 28, 2019 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant |
|
| January 28, 2019 |
AGIO / Agios Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d697775dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) January 22, 2019 (Date of Event Which Requires Filing This Statement) Check the appropriate box to de |
|
| January 7, 2019 |
SRRK / Scholar Rock Holding Corporation / BB BIOTECH AG - SC 13G Passive Investment SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SCHOLAR ROCK HOLDING CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 80706P103 (CUSIP Number) December 28, 2018 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| August 13, 2018 |
TSRO / TESARO, Inc. / BB BIOTECH AG - SC 13G Passive Investment SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 TESARO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 881569107 (CUSIP Number) August 8, 2018 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13 |
|
| August 6, 2018 |
RDUS / Radius Health, Inc. / BB BIOTECH AG - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* Radius Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 750469108 (CUSIP Number) BB Biotech AG Ivo Betschart Schwertstrasse 6 CH-8200 Schaffhausen, Switzerland +41 44 267 67 00 (Name, Address and Tele |
|
| May 10, 2018 |
ESPR / Esperion Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) May 3, 2018 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2018 |
MYOV / Myovant Sciences Ltd. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* MYOVANT SCIENCES LTD. (Name of Issuer) Common Stock (Title of Class of Securities) G637AM102 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2018 |
AGIO / Agios Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2018 |
IONS / Ionis Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* IONIS PHARMACEUTICALS, INC. (formerly Isis Pharmaceuticals, Inc.) (Name of Issuer) Common Stock (Title of Class of Securities) 462222100 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing This Statement) Check the appropriate |
|
| February 14, 2018 |
MGNX / MacroGenics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* MACROGENICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 14, 2018 |
ESPR / Esperion Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2018 |
CDTX / Cidara Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* CIDARA THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 171757107 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 14, 2018 |
ITCI / Intra-Cellular Therapies Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d488190dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* INTRA-CELLULAR THERAPIES INC. (Name of Issuer) Common Stock (Title of Class of Securities) 46116X101 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing This Statement) Check the appropriate box to |
|
| February 14, 2018 |
HALO / Halozyme Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* HALOZYME THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 40637H109 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 10, 2018 |
VYGR / Voyager Therapeutics, Inc / BB BIOTECH AG - SC 13G Passive Investment SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 VOYAGER THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92915B106 (CUSIP Number) January 3, 2018 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| October 27, 2017 |
CDTX / Cidara Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CIDARA THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 171757107 (CUSIP Number) October 24, 2017 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| September 20, 2017 |
Radius Health SC 13D/A (Activist Acquisition of More Than 5% of Shares) SC 13D/A 1 d456933dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* Radius Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 750469108 (CUSIP Number) BB Biotech AG Ivo Betschart Schwertstrasse 6 CH-8200 Schaffhausen, Switzerland +41 44 267 |
|
| August 23, 2017 |
ITCI / Intra-Cellular Therapies Inc. / BB BIOTECH AG - SC 13G Passive Investment SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INTRA-CELLULAR THERAPIES INC. (Name of Issuer) Common Stock (Title of Class of Securities) 46116X101 (CUSIP Number) August 18, 2017 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| June 1, 2017 |
RDUS / Radius Health, Inc. / BB BIOTECH AG - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Radius Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 750469108 (CUSIP Number) BB Biotech AG Ivo Betschart Schwertstrasse 6 CH-8200 Schaffhausen, Switzerland +41 44 267 67 00 (Name, Address and Telep |
|
| March 22, 2017 |
Radius Health SC 13D/A (Activist Acquisition of More Than 5% of Shares) SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Radius Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 750469108 (CUSIP Number) BB Biotech AG Ivo Betschart Schwertstrasse 6 CH-8200 Schaffhausen, Switzerland +41 44 267 67 00 (Name, Address and Telep |
|
| February 14, 2017 |
IONS / Ionis Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* IONIS PHARMACEUTICALS, INC. (formerly Isis Pharmaceuticals, Inc.) (Name of Issuer) Common Stock (Title of Class of Securities) 462222100 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing This Statement) Check the appropriate |
|
| February 14, 2017 |
Cidara Therapeutics SC 13G/A (Passive Acquisition of More Than 5% of Shares) SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CIDARA THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 171757107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 14, 2017 |
MYOV / Myovant Sciences Ltd. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d331389dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MYOVANT SCIENCES LTD. (Name of Issuer) Common Stock (Title of Class of Securities) G637AM102 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designa |
|
| February 14, 2017 |
HALO / Halozyme Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d340919dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* HALOZYME THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 40637H109 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing This Statement) Check the appropriate box to d |
|
| February 14, 2017 |
AGIO / Agios Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2017 |
MGNX / MacroGenics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MACROGENICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 14, 2017 |
ESPR / Esperion Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2017 |
INFI / Infinity Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* INFINITY PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 45665G303 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant |
|
| December 29, 2016 |
MGNX / MacroGenics, Inc. / BB BIOTECH AG - SC 13G Passive Investment SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MACROGENICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) December 28, 2016 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ |
|
| December 28, 2016 |
MYOV / Myovant Sciences Ltd. / BB BIOTECH AG - SC 13G Passive Investment SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MYOVANT SCIENCES LTD. (Name of Issuer) Common Stock (Title of Class of Securities) G637AM102 (CUSIP Number) December 23, 2016 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| September 27, 2016 |
ESPR / Esperion Therapeutics, Inc. / BB BIOTECH AG - SC 13G Passive Investment SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) September 22, 2016 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| April 4, 2016 |
Cidara Therapeutics SC 13G (Passive Acquisition of More Than 5% of Shares) SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CIDARA THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 171757107 (CUSIP Number) March 31, 2016 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| April 4, 2016 |
EX-99.A 2 d168694dex99a.htm EX-99.A Exhibit A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned. BB Biotech AG Date: April 4, 2016 By: /s/ Michael Hutter Signatory Authority Name: Michael Hutter Title: Signatory Authority Date: April 4, 2016 By: /s/ Ivo Betschart S |
|
| February 9, 2016 |
IONS / Ionis Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d128192dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* IONIS PHARMACEUTICALS, INC. ( formerly Isis Pharmaceuticals, Inc.) (Name of Issuer) Common Stock (Title of Class of Securities) 462222100 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing This St |
|
| February 9, 2016 |
HALO / Halozyme Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d128192dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* HALOZYME THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 40637H109 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing This Statement) Check the appropriate box to d |
|
| February 9, 2016 |
INFI / Infinity Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d128192dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) INFINITY PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 45665G303 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing This Statement) Check the appropriate box to |
|
| February 9, 2016 |
AGIO / Agios Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 13, 2015 |
HALO / Halozyme Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d872868dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* HALOZYME THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 40637H109 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing This Statement) Check the appropriate box to d |
|
| February 12, 2015 |
ECYT / Endocyte, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3; Exit Filing)* ENDOCYTE, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29269A102 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 12, 2015 |
IONS / Ionis Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* ISIS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 464330109 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 12, 2015 |
AGIO / Agios Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d872868dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing This Statement) Check the appropriate box to d |
|
| January 13, 2015 |
INFI / Infinity Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G Passive Investment SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INFINITY PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 45665G303 (CUSIP Number) January 8, 2015 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| September 11, 2014 |
AGIO / Agios Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G Passive Investment SC 13G 1 d787834dsc13g.htm SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) September 9, 2014 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursua |
|
| August 7, 2014 |
HALO / Halozyme Therapeutics, Inc. / BB BIOTECH AG - SCHEDULE 13G Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 HALOZYME THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 40637H109 (CUSIP Number) August 1, 2014 (Date of Event Which Requires Filing this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| June 12, 2014 |
RDUS / Radius Health, Inc. / BB BIOTECH AG - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Radius Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 750469108 (CUSIP Number) BB Biotech AG Ivo Betschart Vordergasse 3 CH-8200 Schaffhausen, Switzerland +41 44 267 67 21 (Name, Address and Telephon |
|
| March 5, 2014 |
RDUS / Radius Health, Inc. / BB BIOTECH AG - SCHEDULE 13D AMENDMENT NO. 5 Activist Investment SC 13D/A 1 d688904dsc13da.htm SCHEDULE 13D AMENDMENT NO. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Radius Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 750469108 (CUSIP Number) BB Biotech AG Ivo Betschart Vordergasse 3 CH-8200 Schaffhausen, Switze |
|
| February 12, 2014 |
Amendment No. 1 to Schedule 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* HALOZYME THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 40637H109 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designat |
|
| February 12, 2014 |
ECYT / Endocyte, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ENDOCYTE, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29269A102 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 12, 2014 |
SC 13G/A 1 d674849dsc13ga.htm AMENDMENT NO. 3 TO SCHEDULE 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ISIS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 464330109 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing This Statement) Check th |
|
| August 14, 2013 |
HALO / Halozyme Therapeutics, Inc. / BB BIOTECH AG - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 HALOZYME THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 40637H109 (CUSIP Number) August 5, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| May 3, 2013 |
RDUS / Radius Health, Inc. / BB BIOTECH AG - SCHEDULE 13D AMENDMENT NO. 4 Activist Investment Schedule 13D Amendment No. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Radius Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 750469108 (CUSIP Number) BB Biotech AG Pascal Schmucki Vordergasse 3 CH-8200 Schaffhausen, Switzerland +41 44 267 67 21 (Name |
|
| February 13, 2013 |
ECYT / Endocyte, Inc. / BB BIOTECH AG - SCHEDULE 13G AMENDMENT NO. 1 Passive Investment Schedule 13G Amendment No. 1 United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ENDOCYTE, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29269A102 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursu |
|
| February 13, 2013 |
IONS / Ionis Pharmaceuticals, Inc. / BB BIOTECH AG - SCHEDULE 13G AMENDMENT NO. 2 Passive Investment SC 13G/A 1 d485974dsc13ga.htm SCHEDULE 13G AMENDMENT NO. 2 United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ISIS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 464330109 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing This Statement) Check the a |
|
| February 13, 2013 |
IMGN / Immunogen, Inc. / BB BIOTECH AG - SCHEDULE 13G AMENDMENT NO. 3 Passive Investment SC 13G/A 1 d485974dsc13ga.htm SCHEDULE 13G AMENDMENT NO. 3 United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* IMMUNOGEN, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 45253H101 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing This Statement) Check the appropriate |
|
| August 8, 2012 |
ECYT / Endocyte, Inc. / BB BIOTECH AG - SCHEDULE 13G Passive Investment Schedule 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ENDOCYTE, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29269A102 (CUSIP Number) August 1, 2012 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ¨ |
|
| February 7, 2012 |
OPTR / Optimer Pharmaceuticals Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* OPTIMER PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68401H104 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant t |
|
| February 7, 2012 |
IONS / Ionis Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Isis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 464330109 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 7, 2012 |
IMGN / Immunogen, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d296084dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* IMMUNOGEN, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 45253H101 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the |
|
| February 7, 2012 |
MITI / Micromet, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* MICROMET, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 59509C105 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| January 3, 2012 |
RDUS / Radius Health, Inc. / BB BIOTECH AG - AMENDMENT #3 TO SCHEDULE 13D Activist Investment Amendment #3 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 23, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Radius Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) None (CUSIP Number) BB Biotech AG Pascal Schmucki Vordergasse 3 CH-8200 Schaffhausen, Switzerland +41 44 267 67 21 (Name, Address and Telephone Number of |
|
| November 29, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Radius Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) None (CUSIP Number) BB Biotech AG Pascal Schmucki Vordergasse 3 CH-8200 Schaffhausen, Switzerland +41 44 267 67 21 (Name, Address and Telephone Number of |
|
| July 20, 2011 |
United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Isis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 464330109 (CUSIP Number) July 14, 2011 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o R |
|
| June 3, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Radius Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) None (CUSIP Number) BB Biotech AG Pascal Schmucki Vordergasse 3 CH-8200 Schaffhausen, Switzerland +41 44 267 67 21 (Name, Address and Telephone Number of P |
|
| February 10, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IMMUNOGEN, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 45253H101 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 10, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* OPTIMER PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68401H104 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 10, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MICROMET, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 59509C105 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 10, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ARENA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 040047102 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| August 23, 2010 |
United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Optimer Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68401H104 (CUSIP Number) August 13, 2010 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| May 14, 2010 |
United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ImmunoGen, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45253H101 (CUSIP Number) May 7, 2010 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b) |
|
| March 22, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Micromet, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 59509C105 (CUSIP Number) March 12, 2010 (Date of Event Which Requires Filing this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b |
|
| February 11, 2009 |
sc13gza UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ZYMOGENETICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 98985T109 (CUSIP Number) December 31, 2008 (Date of Event Which Requires Filing this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| January 30, 2009 |
sc13g UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ARENA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 040047102 (CUSIP Number) January 20, 2009 (Date of Event Which Requires Filing this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 31, 2008 |
sc13gza United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ZYMOGENETICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 98985T109 (CUSIP Number) December 31, 2007 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| December 12, 2007 |
OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response. |
|
| April 10, 2007 |
OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response. |
|
| February 14, 2007 |
United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ANADYS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 03252Q408 (CUSIP Number) December 31, 2006 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which |
|
| November 9, 2006 |
OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response. |
|
| February 14, 2006 |
OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2006 Estimated average burden hours per response. |
|
| February 14, 2006 |
OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2006 Estimated average burden hours per response. |
|
| February 14, 2006 |
OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2006 Estimated average burden hours per response. |
|
| February 13, 2006 |
OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2006 Estimated average burden hours per response. |
|
| December 1, 2005 |
sc13g OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| September 19, 2005 |
sc13g OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| June 6, 2005 |
United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* EYETECH PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 302297106 (CUSIP Number) May 24, 2005 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| March 22, 2005 |
EX-99.A 2 w06923exv99wa.htm EXHIBIT 99.A EXHIBIT A Exhibit A Joint Filing Statement Pursuant to Rule 13d-1(k)(1), we, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned. BB Biotech AG Date: March 22, 2005 By: /s/ Pascal Schmucki Signatory Authority Name: Pascal Schmucki Title: Signatory Autho |
|
| March 22, 2005 |
sc13gza OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| February 14, 2005 |
OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| February 14, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EYETECH PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 302297106 (CUSIP Number) December 31, 2004 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 14, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AUXILIUM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 05334D107 (CUSIP Number) December 31, 2004 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 20, 2005 |
sc13gza OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| December 21, 2004 |
OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| December 8, 2004 |
United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Pozen, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 73941U102 (CUSIP Number) December 2, 2004 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant t |
|
| November 12, 2004 |
OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| October 21, 2004 |
OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| August 4, 2004 |
OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| May 17, 2004 |
OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| April 14, 2004 |
OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| February 17, 2004 |
EX-99 3 form4eyetechdec2003.htm FORM 4 JOINT FILER INFORMATION Exhibit 99 Form 4 Joint Filer Information Name: BB Biotech AG(1) Address: Vodergasse 3 8300 Schaffhausen CH/Switzerland Issuer & Ticker Symbol: Eyetech Pharmaceuticals Inc [EYET]) Date of Event Requiring Statement: 2/4/04 Signature: /s/ Roland Maier Signatory Authority for Biotech Growth N.V. and BB Biotech AG (1) Biotech Growth N.V. i |
|
| February 17, 2004 |
EX-99 3 form3eyetechdec2003.htm FORM 3 JOINT FILER INFORMATION Exhibit 99 Form 3 Joint Filer Information Name: BB Biotech AG(1) Address: Vodergasse 3 8300 Schaffhausen CH/Switzerland Issuer & Ticker Symbol: Eyetech Pharmaceuticals Inc [EYET] Date of Event Requiring Statement: 1/29/04 Signature: /s/ Roland Maier Signatory Authority for Biotech Growth N.V. and BB Biotech AG (1) Biotech Growth N.V. i |
|
| November 17, 2003 |
SC 13G 1 w91905sc13g.htm SCHEDULE 13G OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. . . 11 United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cell Therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 150-9 |
|
| June 10, 2003 |
OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| June 10, 2003 |
OMB APPROVAL OMB Number: 3235-0145 Expires: October 31, 2002 Estimated average burden hours per response. |
|
| February 14, 2003 |
OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| February 14, 2003 |
SC 13G/A 1 w83576asc13gza.htm NEUROCRINE BIOSCIENCES SCHEDULE 13G OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response...11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Neurocrine Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of |
|
| February 14, 2003 |
OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| February 14, 2003 |
Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(f)(1), we undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned. |
|
| February 14, 2003 |
OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| February 14, 2003 |
SC 13G/A 1 w83576csc13gza.htm THE MEDICINES COMPANY SCHEDULE 13G OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response...11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* The Medicines Company (Name of Issuer) Common Stock (Title of Class of Securit |
|
| February 14, 2003 |
sc13gza OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| February 14, 2003 |
sc13gza OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| July 1, 2002 |
OMB APPROVAL OMB Number: 3235-0145 Expires: October 31, 2002 Estimated average burden hours per response. |
|
| July 1, 2002 |
OMB APPROVAL OMB Number: 3235-0145 Expires: October 31, 2002 Estimated average burden hours per response. |
|
| August 14, 2001 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 13F Form 13F COVER PAGE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 13F Form 13F COVER PAGE Report for Calendar Year or Quarter Ended: June 30, 2001 Check here if Amendment [ ]; Amendment Number: This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: BB Biotech AG Address: Vordergasse 3 Grafenauweg |
